Livagen 20 mg

Livagen is a short peptide bioregulator developed within the Khavinson school of peptide research at the Saint Petersburg Institute of Bioregulation and Gerontology. Classified as a tetrapeptide oligopeptide with the sequence Lys-Glu-Asp-Ala (KEDA), Livagen was developed to investigate how minimal peptide sequences interact with hepatic tissue and lymphocyte chromatin research models. Its compact structure positions Livagen as a useful research compound for studying tissue-specific peptide signaling in laboratory contexts.

At the cellular and molecular level, Livagen is studied for its proposed ability to engage with chromatin structure and modulate transcriptional activity within hepatocytes and lymphocyte cell models. Research observations within the Khavinson framework suggest that short bioregulator peptides interact with specific DNA regions to influence the expression of genes associated with hepatic enzyme synthesis, hepatocyte renewal, and lymphocyte chromatin organization. These observations are consistent with the broader proposition that short peptides act as gene-expression regulators within tissues from which their parent peptide complexes were originally extracted.

Research interest in Livagen centers on liver-tissue gene expression studies, hepatocyte renewal research models, and lymphocyte chromatin investigations. Comparative work on tissue-specific bioregulators positions Livagen alongside other liver-targeted oligopeptides used to explore peptidergic regulation of hepatic biology in cell-culture and animal research models (Khavinson V.K., Anisimov V.N., 2009, Advances in Gerontology). Additional reports within the Khavinson tradition describe how the KEDA sequence influences heterochromatin decondensation and gene-expression activation in lymphocyte research models, supporting continued laboratory investigation of Livagen in hepatic and chromatin biology research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The development of short peptide bioregulators began in the 1970s at the Military Medical Academy in Saint Petersburg, where Professor Vladimir Khavinson and colleagues isolated peptide fractions from animal tissues that appeared to restore organ-specific function in experimental models. This work led to the founding of the Saint Petersburg Institute of Bioregulation and Gerontology and the systematic study of tissue-derived peptide complexes, including the hepatic peptide complex from which Livagen was later derived.

Livagen was identified within this research program as a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Ala (KEDA), associated with hepatic tissue and lymphocyte research models. Subsequent biochemical and molecular investigations explored how this peptide interacts with chromatin and influences heterochromatin decondensation, supporting the hypothesis that minimal peptide sequences can act as tissue-specific gene-expression modulators within hepatocyte and lymphocyte cell systems.

Today, Livagen is positioned within the wider family of Khavinson-school oligopeptides studied for liver-tissue gene expression, hepatocyte renewal research, and lymphocyte chromatin research in laboratory contexts.

1. Chromatin Interaction and Heterochromatin Decondensation

Within the Khavinson framework, Livagen is proposed to interact with specific regions of double-stranded DNA and associated chromatin proteins, where it has been reported to influence heterochromatin decondensation in lymphocyte research models. This proposed mode of action positions Livagen as a tool for investigating peptide-mediated chromatin remodeling and gene-expression regulation.

2. Hepatocyte Signaling and Liver-Tissue Pathways

Research observations suggest that Livagen engages with intracellular signaling pathways relevant to hepatocyte function, including pathways associated with liver-tissue enzyme expression research and hepatocyte renewal research models. These observations make Livagen a useful compound for exploring tissue-specific peptide signaling in hepatic cell-culture systems.

3. Lymphocyte and Immune-Cell Chromatin Research

Comparative work on short peptide bioregulators indicates that the KEDA sequence is associated with chromatin-organization changes in lymphocyte cell models, including studies of aged lymphocyte populations. In lymphocyte research models, Livagen is investigated for its role in chromatin decondensation studies, transcriptional reactivation research, and age-related chromatin organization investigations.

4. Adaptive and Homeostatic Signaling

Khavinson-school bioregulators are described as adaptive peptide regulators that operate under physiological stress conditions. Livagen is studied for its proposed contribution to hepatic-tissue homeostasis research, including models of age-related decline in liver-cell signaling and oxidative stress adaptation.

Research Applications

Conclusion

Livagen is a Khavinson-school short peptide bioregulator with the sequence Lys-Glu-Asp-Ala, studied for its proposed role in liver-tissue gene expression, hepatocyte renewal research, and lymphocyte chromatin research. Its compact tetrapeptide structure and dual hepatic-lymphocyte positioning make Livagen a valuable laboratory compound for exploring peptidergic regulation of gene expression in research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.